secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000939767-25-000074
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M
--------------------------------------------------------------------------------

- Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).
- GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.
- Increasing 2025 full year net product revenues and total revenues guidance by $100M.
- CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.
- Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/0000939767-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000074/exel-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000939767-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer